Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
about
Ion channels and apoptosis in cancerMutant Cbl proteins as oncogenic drivers in myeloproliferative disordersA seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohortsAMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy.Spirotetronate polyketides as leads in drug discovery.A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.Emerging Bcl-2 inhibitors for the treatment of cancer.RhoA/ROCK/PTEN signaling is involved in AT-101-mediated apoptosis in human leukemia cells in vitro and in vivo.Targeting protein-protein interactions for therapeutic intervention: a challenge for the future.The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cellsFunction of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancerInhibitors of Bcl-2 protein family deplete ER Ca2+ stores in pancreatic acinar cells.Genetic inhibition of protein kinase Cε attenuates necrosis in experimental pancreatitis.Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivoThe BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent mannerInterrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapyQuercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation.Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivoBroad targeting of resistance to apoptosis in cancer.Epstein-Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells.Mitochondrial permeability transition pore as a selective target for anti-cancer therapyBCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.Eliminating encephalitogenic T cells without undermining protective immunityInhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.Targeting the BCL-2 family in malignancies of germinal centre origin.PAR-4 as a possible new target for pancreatic cancer therapy.Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.LDH-C4: a target with therapeutic potential for cancer and contraception.The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.Apoptosis regulation at the mitochondrial outer membrane.Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cellsPan-BH3 mimetic S1 exhibits broad-spectrum antitumour effects by cooperation between Bax and Bak.Effect of miR-451 on the biological behavior of the esophageal carcinoma cell line EC9706.A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1.Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention.The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.
P2860
Q27005947-078E78A1-4B68-4B12-874D-309B7B01AD74Q28307750-57D1970A-2B8F-4EA0-A89B-533FED55C01FQ28728722-AA9D7D97-6124-42EB-953D-BEA220208CECQ30505415-2906DA5F-FB86-4E4D-BF73-9AC41138D4A1Q30872494-B487F649-01F0-400E-BA01-04CBC4C7C055Q33415717-D2C57CA9-3195-4529-B213-4BAC844FD659Q33415855-7A019E9A-C902-4527-B14E-D41A3A62095EQ33682689-F6F03D0A-BA21-425E-AB1E-74250D063C07Q33695176-36A6B955-D48B-4737-B32B-5A18CCA80C33Q33852396-DB3764ED-1F41-458F-BDB8-078563DC3574Q34055891-5E8F0865-AC2D-42D2-8957-9ABFD60E27CFQ34094975-A93CE74A-BE3A-4BC7-BFC6-C435E1B9DEE4Q34118004-5461B18D-C801-41A9-8D32-72E63BFCB651Q34131089-1564673A-70CC-4CBE-905D-17F8BAEC4055Q34581860-2D5D33B5-E59A-4AE2-8A48-1BCA9111BA19Q34685414-9B778176-D3DA-4705-86CF-A3BDBF9D98D0Q34687012-237F31CE-757B-47CC-B138-FE0A5FAD5859Q34793542-30E07706-62BC-435C-AC0B-240C924815DEQ35099238-5F46630E-8BA8-4B50-A6AB-3D9CDF3F1C04Q35125652-1BFE03C7-592A-48C6-B489-9D521D0BC31FQ35387996-45164B0A-36FC-4A41-A1F6-27D6161ABC7DQ36483749-E2B94363-C523-4928-9BE7-47CF559CB7F4Q36526103-4F6E93AE-5075-4EB5-8136-0202B2DA1EB5Q36668047-210F3109-6A14-4F86-8EAC-617C9EBBB5F8Q37268123-65B7B47B-666A-4D0D-BA12-8928C30075B8Q37412980-B4EDE07E-08E0-4461-9A8C-763189075025Q37460333-E18066B7-E641-4B5E-867E-C6D00E6593D2Q37634558-8DCA5D6E-2718-43AA-A583-3F3E257E6571Q37738894-4D604984-3C42-4560-B821-08743331A6AAQ37761935-D006B123-0D22-48C7-8164-07CC7D6F0015Q38034661-BBCDF341-D783-4942-B11F-7FE263CDA0F1Q38041423-D0A4F384-1972-418C-8547-4927B3686F07Q38181031-8EA9AABA-8155-41FE-A680-F326B83701ACQ38825797-30566DE4-4437-4A4F-BDE0-489D40887B1EQ38850608-5DEFA74E-248D-4638-8734-B7C7C9FB2F7FQ39171337-1276898E-0077-4AB7-A5F5-AE43955057B1Q39262279-BC0397A8-FDC3-4DCC-963D-09C3EDB4F207Q39700222-2E9D0C05-4264-4801-AFDD-D1F8BFF8BF78Q39707773-6570B6D1-6E95-4442-B4A5-2749B65A6D9FQ39819844-4711F4B3-CC65-4533-A840-075F1C90269C
P2860
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
@en
type
label
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
@en
prefLabel
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
@en
P2860
P356
P1476
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy
@en
P2093
Ramzi M Mohammad
P2860
P356
10.1002/JCP.21567
P50
P577
2009-01-01T00:00:00Z